Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Details of PMT Small Merger
29
2024.11
Kangstem Biotech announced on the 28th that it has decided to merge with its affiliate, Primorye Stereotherapeutics.
Kangstem Biotech announced on the 28th that it has decided to merge with its affiliate, Primorye Stereotherapeutics.
With this merger, the company will actively promote the regenerative medicine business using exosomes. Kangstem Biotech has received final approval from the Japanese Ministry of Health, Labour and Welfare for its GMP center and possesses a deep understanding of the Japanese regenerative medicine market. Furthermore, Primorye Stereotherapeutics' exosomes are distinguished by their pharmaceutical-grade quality, having undergone both quality inspection and animal testing. This positions the company to quickly enter the Japanese market, where regenerative medicine using exosomes is actively used in skin clinics and plastic surgery.
In Korea, the revision of the Biotechnology Act enables business entry in the regenerative medicine business category, and clinical research and treatment using exosomes, which have high patient demand and relatively low risk, are expected to materialize, especially in the Free Regulatory Zone. Sales are expected to be realized from 2025.
The company will also accelerate the development of exosome-based osteoarthritis therapies for animals, a market with significant demand. Compared to human medicine, animal medicines often involve simpler processes, such as production procedures, which can reduce both development costs and time. The company has already established the potential for entering the veterinary drug market in partnership with a leading global veterinary pharmaceutical company and is set to swiftly expand its veterinary drug business.
Additionally, Kangstem Biotech is pushing forward with the commercialization of PMS-101, an exosome-based burn treatment. PMS-101 has demonstrated non-clinical data showing a 45% increase in skin tissue regeneration compared to the untreated group, and a 23% increase compared to the currently marketed treatment. The company has also received approval for a Phase 1/2a clinical trial in Australia, and expected to deliver results relatively quickly compared to other therapies, given the nature of burn injuries, which allow for rapid assessment of treatment effects, as well as Kangstem Biotech's clinical expertise.
The company is working to secure technology based on DDS (Drug Delivery System), a next-generation drug delivery method. This biocompatible technology has no limitations on the types of drugs it can deliver. Preliminary research has already confirmed that artificial nanovesicles loaded with ASO (Anti-Sense Oligonucleotide), a molecule that inhibits cancer formation, and chemical anticancer agents, can suppress cancer tissue formation in the body.
Through these efforts, Kangstem Biotech aims to commercialize exosomes, which are expected to generate rapid sales, and make them a key source of revenue while covering initial clinical trial costs.